The results ensure conclusions drawn by Bagli et al. [1], who conducted a research that involved ten patients diagnosed with CRAO who obtained HBOT. In combination with receiving twenty sessions of HBOT, oral acetazolamide and topical beta-blockers were being administered to the patients within the